【TMCLIFE 0101 交流专区】TMC生命科学

Tony-Pua

第四季业绩创记录 TMC派息1.83%
Wong Ee Lin/theedgemarkets.com
October 29, 2018 19:56 pm +08

（吉隆坡29日讯）TMC生命科学（TMC Life Sciences Bhd）录得十年来最佳第四季业绩表现，净利与营业额双双创新高。

截至今年8月31日止第四季（2018财年第四季），净利按年增长2.2%至1134万令吉或每股0.65仙，2017财年第四季报1110万令吉（每股0.64仙），归功于总营运开支减少。病人及处理的病例数量增加，把营业额按年推高了9.89%，至4319万令吉。

根据彭博社数据，这是该公司在至少2008财年以来，最好的第四季营业额与净利数据。该公司于2005年在大马交易所挂牌。

该公司宣布，在截至今年8月杪财年（2018财年）派发每股1.83%或0.183仙单层终期股息，并在稍后宣布享有权益日期及付款日期。

该公司在2018财年净赚2806万令吉或每股1.62仙，比上财年的2603万令吉或每股1.5仙，按年上涨7.77%；营业额则按年上升11.42%至1亿6904万令吉，上财年为1亿5171万令吉。这是该公司连续五年获得按年净利增长。

展望未来，该公司将继续采取措施，通过引入更多服务来保持增长，同时加大宣传和营销力度，确保其成为私人患者的首选医疗保健服务供应商。

“公司在哥打白沙罗Thomson医院的扩建项目已于2018年7月完成打桩工作，建设工程正按计划进行；位于柔佛新山的Thomson Iskandar医疗中心正在获得相关监管部门的批准，预计将于2018年底开始打桩工作。”

（编译：魏素雯）

0101                 TMCLIFE                 TMC LIFE SCIENCES BHD

Quarterly rpt on consolidated results for the financial period ended 31/08/2018

Quarter: 4th Quarter Financial Year End: 31/08/2018 Report Status: Unaudited Submitted By: Current Year Quarter Preceding Year Corresponding Quarter Current Year to Date Preceding Year Corresponding Period 31/08/2018 31/08/2017 31/08/2018 31/08/2017 RM '000 RM '000 RM '000 RM '000 1 Revenue 43,194 39,307 169,039 151,712 2 Profit/Loss Before Tax 10,716 6,747 33,440 27,139 3 Profit/(loss) attributable to ordinary equity holders of the parent 11,340 11,096 28,056 26,034 4 Net Profit/Loss For The Period 11,340 11,096 28,056 26,034 5 Basic Earnings/Loss Per Shares (sen) 0.65 0.64 1.62 1.50 6 Dividend Per Share (sen) 0.18 0.17 0.18 0.17 As At End of Current Quarter As At Preceding Financial Year End 7 Net Assets Per Share (RM) 0.4300 0.4100

icy97

Type	Announcement
Subject	OTHERS
Description	Proposed Final Dividend
The Board of Directors of TMC Life Sciences Berhad is proposing a single-tier final dividend of 1.83% or 0.183 sen for the 12 months financial year ended 31 August 2018 to the shareholders for approval at the forthcoming annual general meeting. The entitlement and payment dates of the aforesaid dividend will be announced at a later date. This announcement is dated 29 October 2018.

icy97

Type	Announcement
Subject	OTHERS
Description	TMC LIFE SCIENCES BERHAD (TMC OR THE COMPANY)-        AWARD OF CONTRACT
INTRODUCTION The Company wishes to announce that BB Waterfront Sdn. Bhd. (“BBWF”), a wholly owned subsidiary of the Company had on 31 October 2018 awarded the Piling Works to Putra Perdana Construction Sdn. Bhd. for the Proposed 33-Storey Mixed Development at PTB 24075, Jalan Stulang Darat, Stulang Laut, Bandar Johor Bahru, Daerah Johor Bahru (“the Contract”) to facilitate the construction work on Thomson Iskandar Medical Hub. CONTRACT PERIOD The Contract period will be for a period of Forty (40) weeks, commencing on 26 November 2018 and to be completed by or before 2 September 2019. CONTRACT SUM The Contract Sum is Ringgit Malaysia Forty Eight Million Six Hundred Ninety-Six Thousand Six Hundred Twenty Eight (RM48,696,628) only. RISKS The Board of Directors of the Company does not envisage any specific risk to be associated with the Contract, apart from the operational and financial costs. FINANCIAL EFFECTS The Contract will not have any effect on the issued and paid-up share capital of the Company and is not expected to have any material effect on the earnings, earnings per share, net asset value and gearing of TMC Group during the Contract period. The Contract will be funded through internally-generated funds. DIRECTORS’ AND MAJOR SHAREHOLDERS’ INTEREST None of the Directors and/or major shareholders of the Company and/or persons connected with them, have any interest, direct or indirect, in the Contract. This announcement is dated 31 October 2018.

icy97

Type	Announcement
Subject	OTHERS
Description	Thomson Medical Group Limited ("TMGL")- Unaudited Third Quarterly Financial Statement for the financial period ended 30 September 2018.
The Board of Directors of TMC Life Sciences Berhad (“The Company”) wishes to inform that Thomson Medical Group Limited (“TMGL”), the holding company of the Company had announced the unaudited third quarterly financial statement  announcement for the financial period ended 30 September 2018. Please refer to the below announcement on the website of Singapore Exchange released by TMGL: http://www.bursamalaysia.com/market/listed-companies/company-announcements/5970073 This announcement is dated 9 November 2018.

icy97

新加坡康盛医院股东-1对1比例换rsp控股股权
http://www.chinapress.com.my/20181112/新加坡康盛医院股东-1对1比例换rsp控股股权/

Type	Announcement
Subject	OTHERS
Description	Thomson Medical Group Limited ("TMGL")- Proposed Distribution in Specie by way of Capital Reduction
The Board of Directors of TMC Life Sciences Berhad ("the Company") wishes to inform that TMGL, the holding company has on 12 November 2018 released an announcement to Singapore Exchange pertaining to proposing to distribute its entire interests in its design and engineering and hospitality businesses to its shareholders via a distribution in specie by way of a capital reduction . This announcement is dated 12 November 2018. http://www.bursamalaysia.com/market/listed-companies/company-announcements/5970293

icy97

TMC LIFE SCIENCES BERHAD

EX-date	11 Feb 2019
Entitlement date	13 Feb 2019
Entitlement time	05:00 PM
Entitlement subject	Final Dividend
Entitlement description	Final Single-Tier Dividend of 0.183 sen per ordinary share in respect of the financial year ended 31 August 2018.
Period of interest payment	to
Financial Year End	31 Aug 2018
Share transfer book & register of members will be	to   closed from (both dates inclusive) for the purpose of determining the entitlement
Registrar or Service Provider name, address, telephone no	TRICOR INVESTOR & ISSUING HOUSE SERVICES SDN BHDUnit 32-01, Level 32, Tower A,Vertical Business Suite, Avenue 3, Bangsar South,No. 8, Jalan Kerinchi59200 Kuala LumpurTel:03-27839299Fax:03-27839222
Payment date	27 Feb 2019
a.Securities transferred into the Depositor's Securities Account before 4:00 pm in respect of transfers	13 Feb 2019
b.Securities deposited into the Depositor's Securities Account before 12:30 pm in respect of securities exempted from mandatory deposit
c. Securities bought on the Exchange on a cum entitlement basis according to the Rules of the Exchange.
Number of new shares/securities issued (units) (If applicable)
Entitlement indicator	Currency
Currency	Malaysian Ringgit (MYR)
Entitlement in Currency	0.0018

icy97

Date of change	25 Jan 2019
Name	MR ROY QUEK HONG SHENG
Age	48
Gender	Male
Nationality	Singapore
Designation	Director
Directorate	Executive
Type of change	Resignation
Reason	Part of Thomson Medical Group Limited's strategy to put in place strong local leadership as it prepares for its next phase of rapid growth and development.

icy97

Date of change	25 Jan 2019
Name	CIK WAN NADIAH BINTI WAN MOHD ABDULLAH YAAKOB
Age	34
Gender	Female
Nationality	Malaysia
Designation	Executive Director
Directorate	Executive
Type of change	Appointment

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Degree	MSc Public Health Nutrition	London School of Hygiene and Tropical Medicine, UK
2	Others	AB cumLaude in Biochemical Sciences	Harvard College

Working experience and occupation

Ms. Wan Nadiah Binti Wan Mohd Abdullah Yaakob ("Ms. Nadiah Wan"), was appointed as Chief Executive Officerof Thomson Hospitals Sdn Bhd and Group Chief Corporate Officer of TMC Life Sciences Berhad on 19 June 2017.Prior to joining Thomson Hospitals Sdn Bhd and the Company, Ms. Nadiah Wan worked in Sunway Medical Centre as Chief Operating Officer (Clinical Services) after being promoted from Director of Business Development and Corporate Communications in October 2016. She started her career at The Boston Consulting Group in 2007 as an Associate Consultant before joining Sunway Group as Manager, Strategy and Corporate Development in 2010.

icy97

Date of change	01 Feb 2019
Name	MR KAN KHEONG NG
Age	63
Gender	Male
Nationality	Malaysia
Type of change	Redesignation
Previous Position	Non Executive Director
New Position	Executive Director
Directorate	Executive

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Degree	Business Administration	Royal Melbourne Institute of Technology

Working experience and occupation

Mr. Kan Kheong Ng ("Mr. Barry Kan") was appointed as the Non Independent Non-Executive Director of TMC Life Science Berhad on 2 June 2015. He is a veteran of almost 30 years in the automotive industry with rich and vast experience in managing various illustrious global brands during his career with renowned regional dealership, Wearnes Automotive, headquartered in Singapore. Prior to that, he was with the Port Authority of Singapore for 7 years. As General Manager at Malayan Motors (a division then of Wearnes Automotive Pte Ltd), his portfolio included the Rolls-Royce, Bentley, Jaguar and Volvo Trucks franchises in Singapore. He was also responsible for theintroduction of some of the brands into new territories such as Brunei, Indonesia, Taiwan and Thailand. In addition to the strategic management of the business, he took personal interest in Customer Relationship Management and Aftersales operations, which resulted in a high level of clientele retention for the luxury automotive brands.Promoted to Managing Director of the Prestige Division of Wearnes Automotive, he was instrumental in the acquisition of new brands which included Bugatti, Land Rover and McLaren. He was also the key representative of the company for the high-society clientele which included the Captains of Industry as well as esteemed members of Royal families within the region.When the exciting opportunity arose to develop the integrated automotive hub in Nusajaya, Iskandar Malaysia, he joined Fastrack Autosports (Iskandar) Pte. Ltd. to conceptualise and execute the project, in partnership with UEW Sunrise Berhad. Mr. Kan leads the joint venture company, Fastrack Iskandar Sdn. Bhd. as its Chief Executive Officer.

icy97

Type	Announcement
Subject	OTHERS
Description	Press Release
Please refer to the Press Release dated 23 January 2019. Please refer attachment below.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6044045

Attachments Press Release - New Board Appointments (23 Jan 2019).pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Nov 2018

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Nov 2018	30 Nov 2017	30 Nov 2018	30 Nov 2017
		$$'000	$$'000	$$'000	$$'000

1	Revenue	47,164	41,728	47,164	41,728
2	Profit/(loss) before tax	9,406	8,324	9,406	8,324
3	Profit/(loss) for the period	7,070	6,329	7,070	6,329
4	Profit/(loss) attributable to ordinary equity holders of the parent	7,070	6,329	7,070	6,329
5	Basic earnings/(loss) per share (Subunit)	0.41	0.36	0.41	0.36
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4300		0.4300

icy97

Date of change	01 Feb 2019
Name	MR WILSON SAM
Age	42
Gender	Male
Nationality	Singapore
Designation	Alternate Director
Directorate	Executive
Type of change	Appointment

Qualifications

No	Qualifications	Major/Field of Study	Institute/University	Additional Information
1	Degree	Bachelor of Business Studies (Honours) with a major in financial analysis and a minor in accountancy	Nanyang Technological University

Working experience and occupation

Mr. Sam ("Mr. Sam") has close to 20 years of experience in investments, advisory and financial analysis and is currently the Senior Vice President of Kestrel Capital Pte. Ltd., a Singapore headquartered private investment company, where he heads the investments and merger and acquisitions team. Recent notable transactions include the acquisition of Valencia Club de Futbol, the initial public offering of Secura Group and the very substantial acquisition of Sasteria Pte. Ltd. Mr. Sam was the Vice President of Rowsley Limited where he managed its investment activities before joining Kestrel Capital Pte Ltd in 2013.Prior to this, Mr. Sam held various positions with regional and international banks, specialising in corporate finance and merger and acquisitions and was involved in numerous initial public offerings, financial advisory and merger and acquisition transactions. He started his career as a senior officer in a Singapore government statutory board in 2000 before joining a US multinational company in 2001.Mr. Sam is also a director of Mint Media Sports Limited, a sports entertainment and media company and Catpital Private Limited, an investment company.

icy97

Type	Announcement
Subject	OTHERS
Description	Thomson Medical Group Limited ("TMGL")-Unaudited 4th Quarter Financial Statement Announcement for the Financial Period Ended 31 December 2018
The Board of Directors of TMC Life Sciences Berhad (“The Company”) wishes to inform that Thomson Medical Group Limited (“TMGL”), the holding company of the Company had announced the Unaudited 4th Quarter Financial Statement Announcement for the Financial Period Ended 31 December 2018. Please refer to the below announcement on the website of Singapore Exchange released by TMGL: http://www.bursamalaysia.com/market/listed-companies/company-announcements/6082889 This announcement is dated 28 February 2019

icy97

Type	Announcement
Subject	OTHERS
Description	Thomson Medical Group Limited ("TMGL")- Memorandum of Understanding
The Board of Directors of TMC Life Sciences Berhad ("the Company") wishes to inform that TMGL, the holding company has on 12 March 2019 released an announcement to Singapore Exchange pertaining to TMGL has on 7 March 2019 entered into a Memorandum of Understanding with Brigham Health International, LLC ("BHI") and Dana-Farber Cancer Institute, Inc., ("DFCI") in relation to exploring a potential collaboration to support the growth and advancement of Thomson Medical's hospital projects in the region and to promote the advancement of healthcare delivery, education and research with a focus on women's health and oncology. Please refer to the below announcement on the website of Singapore Exchange which released by TMGL: http://www.bursamalaysia.com/market/listed-companies/company-announcements/6094313 This announcement is dated 13 March 2018.

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 28 Feb 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		28 Feb 2019	28 Feb 2018	28 Feb 2019	28 Feb 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	45,160	39,711	92,324	81,439
2	Profit/(loss) before tax	8,223	6,403	17,629	14,727
3	Profit/(loss) for the period	6,206	4,760	13,276	11,089
4	Profit/(loss) attributable to ordinary equity holders of the parent	6,206	4,760	13,276	11,089
5	Basic earnings/(loss) per share (Subunit)	0.36	0.27	0.76	0.64
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4300		0.4300

icy97

Expiry/Maturity of the securities

TMC LIFE SCIENCES BERHAD

Instrument Category	Securities of PLC
Instrument Type	Warrants
Type Of Expiry	Expiry/Maturity of the securities
Mode of Satisfaction of Exercise/Conversion price	Cash
Exercise/ Strike/ Conversion Price	Malaysian Ringgit (MYR) 0.7500
Exercise/ Conversion Ratio	1:1
Settlement Type / Convertible into	Physical (Shares)
Last Date & Time of Trading	03 Jun 2019 05:00 PM
Date & Time of Suspension	04 Jun 2019 09:00 AM
Last Date & Time for Transfer into Depositor's CDS a/c	14 Jun 2019 04:00 PM
Date & Time of Expiry	21 Jun 2019 05:00 PM
Date & Time for Delisting	24 Jun 2019 09:00 AM

http://www.bursamalaysia.com/market/listed-companies/company-announcements/6162993

Attachments Notice to Warrantholders - Expiry of Warrants 2015-2019.pdf

icy97

tmc生科第三季赚836万
http://www.enanyang.my/news/20190730/tmc生科第三季赚836万/

SUMMARY OF KEY FINANCIAL INFORMATION 31 May 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 May 2019	31 May 2018	31 May 2019	31 May 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	51,130	44,406	143,454	125,845
2	Profit/(loss) before tax	10,888	7,997	28,517	22,724
3	Profit/(loss) for the period	8,357	5,627	21,633	16,716
4	Profit/(loss) attributable to ordinary equity holders of the parent	8,357	5,627	21,633	16,716
5	Basic earnings/(loss) per share (Subunit)	0.48	0.32	1.25	0.96
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4400		0.4300

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Aug 2019

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Aug 2019	31 Aug 2018	31 Aug 2019	31 Aug 2018
		$$'000	$$'000	$$'000	$$'000

1	Revenue	51,524	43,194	194,978	169,039
2	Profit/(loss) before tax	9,634	10,373	38,151	33,097
3	Profit/(loss) for the period	6,463	11,080	28,096	27,796
4	Profit/(loss) attributable to ordinary equity holders of the parent	6,463	11,080	28,096	27,796
5	Basic earnings/(loss) per share (Subunit)	0.37	0.64	1.62	1.60
6	Proposed/Declared dividend per share (Subunit)	0.20	0.18	0.20	0.18
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	0.4400		0.4300

icy97

Change in Financial Year End

TMC LIFE SCIENCES BERHAD

Old financial year end	31 Aug 2020
New financial year end	30 Jun 2020

Remarks :

The Board of Directors of TMC Life Sciences Berhad ('the Company') had approved the change in the financial year end ('FYE') of the Company from 31 August to 30 June. The next set of Audited Financial Statements shall be for a period of 10 months from 1 September 2019 to 30 June 2020 and thereafter, the FYE shall be 30 June for each subsequent year. The change in the FYE of the Company from 31 August to 30 June annually is to coincide with the FYE of its holding company.

icy97

Type	Announcement
Subject	OTHERS
Description	TMC Life Sciences Berhad ('the Company') - Proposed Single-Tier Final Dividend
The Board of Directors of the Company has proposed a single-tier final dividend of 2.013% or 0.2013 sen per ordinary share for the financial year ended 31 August 2019 subject to the shareholders' approval at the forthcoming Seventeenth Annual General Meeting of the Company. The entitlement and payment dates of the aforesaid dividend will be announced at a later date. This announcement is dated 24 October 2019.